StreetAlpha.app
Home › Stocks › EMBC

Embecta Corp. (EMBC)

Healthcare
$6.02
▼ −2.75%
LAST CLOSE · NOV 20

Embecta makes pen needles, insulin syringes and safety injection devices for people with diabetes. It last closed at $6.02 on Nov 20, down 2.75% on the day. The next earnings report for EMBC is expected around Tue, Nov 24, 2026. For the quarter ended Jun 2026, EMBC reported EPS of $0.36 on revenue of $271.7M, with revenue down 8.1% from a year ago. Over its last 8 reports the stock moved an average of 20.0% the session after earnings. Over the last 12 months EMBC insiders bought $558K of stock on the open market and sold $37K, according to SEC Form 4 filings.

AI Auto Pilots
Is EMBC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold EMBC.

Key Stats

Last 12 months
Results
Revenue
$1.0B
−7.6% vs a year ago
Net income
$87.5M
+4.7% vs a year ago
EPS (diluted)
$1.47
+3.5% vs a year ago
Free cash flow
$164.6M
16.2% margin
Valuation
Market cap
$341.1M
56.7M shares
P/E
4.1
Price over 12 month EPS
Price to sales
0.3
Market cap over revenue
Dividend yield
7.64%
$0.46 a share over 12 months
Balance sheet
Cash & equivalents
$214.7M
At Jun 30
Debt
$1.5B
At Jun 30
Shareholder equity
−$612.7M
Shares outstanding
56.7M
At Jul 31
Fiscal year endsSeptember
ExchangeNasdaq
Financials history
FY2021: $1.2B$1.2BFY2021FY2022: $1.1B$1.1BFY2022FY2023: $1.1B$1.1BFY2023FY2024: $1.1B$1.1BFY2024FY2025: $1.1B$1.1BFY2025

From EMBC's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 7). Last 12 months adds up the four latest quarters.

Next report
Nov 24
Estimated date · Time not announced
Reported EPS
$0.36
Quarter ended Jun 2026
Year ago EPS
$0.78
−53.8% on a GAAP basis
Revenue
$271.7M
−8.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Sep 2024: $0.24Sep '24Dec 2024: $0.00Dec '24Mar 2025: $0.40Mar '25Jun 2025: $0.78Jun '25Sep 2025: $0.44Sep '25Dec 2025: $0.74Dec '25Mar 2026: -$0.07Mar '26Jun 2026: $0.36Jun '26Latest $0.36
Revenue by quarter
Sep 2024: $286.1MSep '24Dec 2024: $261.9MDec '24Mar 2025: $259.0MMar '25Jun 2025: $295.5MJun '25Sep 2025: $264.0MSep '25Dec 2025: $261.2MDec '25Mar 2026: $221.8MMar '26Jun 2026: $271.7MJun '26Latest $271.7M
How EMBC moved after its last 8 reports
Average move the session after a report ±20.0%
Aug 7, 2026Time not announced+26.3%
May 5, 2026Time not announced−57.8%
Feb 5, 2026Time not announced−7.8%
Nov 25, 2025Time not announced−7.2%
Aug 8, 2025Time not announced+18.5%
May 9, 2025Time not announced−10.0%
Feb 6, 2025Time not announced−2.6%
Nov 26, 2024Time not announced+29.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on EMBCStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on EMBC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on EMBC

Technical Analysis

EMBC · as of the Nov 20 close · updated each morning
Downtrend

The stock is 5% below its 20 day and 1% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 44). The nearest support is the Pivot S1 at $5.81, and the nearest resistance the 200 day average at $6.06.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 5.6%/day
Key levels
$14.8052 week high+145.8%
$6.3420 day average+5.3%
$6.31Pivot R1+4.8%
$6.16Swing high (Oct 7)+2.3%
$6.11Pivot+1.5%
$6.0650 day average+0.7%
$6.06200 day average+0.7%
$6.02Last close
$5.81Pivot S1−3.5%
$5.78Swing low (Nov 6)−4.0%
$5.16100 day average−14.3%
$2.7752 week low−54.0%
Indicators
RSI (14)44.24Middle of its rangeNeutral
MACD0.01Below its signal lineBearish
Stochastic31.7Middle of its rangeNeutral
ADX (14)17.1No clear trend
Williams %R-76.2Oversold below −80, overbought above −20Neutral
CCI (20)-103.0Oversold below −100, overbought above 100Oversold
Rate of change−2.8%Change over 10 sessionsBearish
ATR (14)$0.34Typical daily range, 5.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Below
What happened before, for EMBC

What happened before

See how EMBC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow EMBC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How EMBC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for EMBCHow many large options trades hit EMBC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

EMBC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●140 buying vs 131 selling
  • ▲Held by funds +3.3 pts
  • ●Funds holding -3
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding323326−0.9%
In funds' top 1021+100.0%
Held by funds92.3%89.0%+3.3 pts
New / increased59 / 8160 / 800.0%
Reduced / sold out73 / 5875 / 72−10.9%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EMBC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

EMBC Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$558K4 buys · 4 insiders
Sold$37K1 sale · 1 insider
Cluster buy: 4 insiders bought $558K between Aug 12 and Aug 12.
2026-08 bought $558K2026-09 sold $37KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 4Milton Mayo MorrisDirectorSale6,293$5.88$37K
Aug 12Robert J. HombachDirectorBuy45,000$4.97$224K
Aug 12Jeffrey Z MannPres, Pharm Svc&Prod Mgmt, CLOBuy20,000$4.99$100K
Aug 12Jacob ElguiczeSVP and CFOBuy20,000$4.67$93K
Aug 12Devdatt KurdikarPresident and CEOBuy30,000$4.70$141K
May 23, 2025David F MelcherDirectorBuy10,000$10.60$106K
Every insider buy and sale for EMBC over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See EMBC insider trades →

From SEC Form 4 filings by EMBC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EMBC is in one of them and how their past EMBC trades turned out.

EMBC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EMBC in an article yet. Here's the latest on the wider market.

About Embecta

Embecta is a medical device company focused on helping people with diabetes manage insulin injections. Its main products are pen needles, insulin syringes and safety injection devices, which are designed to work with insulin pens and vials and to help protect users and healthcare workers from needlestick injuries. The company sells to patients, retailers, hospitals, pharmacies and other healthcare providers in many countries. It is based in Parsippany, New Jersey.

Headquarters
Parsippany, NJ